Accelerating Formulation Development for a Bispecific Antibody Program
Formulation development for bispecific antibodies can require careful screening and optimization because formulation conditions can influence protein stability and overall product quality. When the development timeline is highly constrained, an efficient screening strategy becomes particularly important, especially when only a limited number of screening rounds are available.
In this case, Protheragen supported formulation development for a bispecific antibody program under an accelerated timeline. Only two rounds of formulation screening were available, leaving limited tolerance for unsuccessful screening cycles.
By leveraging the team's formulation development experience and optimizing the screening workflow, a suitable formulation was identified in approximately 11 weeks, compared with a typical industry development timeframe of approximately 3–5 months. Subsequent formulation confirmation demonstrated good stability of the selected formulation, and the program successfully progressed to IND submission.
The Challenge
Limited Screening Opportunities Under an Aggressive Timeline
The primary challenge was the highly compressed development timeline.
Only two rounds of formulation screening were available for the project, resulting in a relatively low tolerance for unsuccessful screening cycles. A conventional screening workflow could increase the risk of consuming available development time before a suitable formulation was identified.
The formulation development strategy therefore needed to:
- Maximize the information obtained from each screening round;
- Efficiently narrow down formulation candidates;
- Leverage prior formulation development experience;
- Identify a suitable formulation within the required timeline.
The key challenge was therefore not simply to screen more formulations, but to design a more efficient screening strategy within a very limited development window.
Our Strategy
- Leverage Formulation Development Experience
The formulation development team leveraged its previous experience with antibody formulation development to establish a focused screening strategy.
Rather than relying on an unnecessarily broad or sequential screening process, the team used existing formulation knowledge to determine appropriate screening priorities and streamline the experimental workflow.
This experience-based approach helped maximize the value of the two available screening rounds.
- Optimize the Formulation Screening Workflow
The screening workflow was rationally optimized to improve development efficiency.
The formulation candidates were evaluated through a structured screening process, allowing unsuitable candidates to be progressively eliminated and promising candidates to advance to subsequent evaluation.
The workflow was designed to make effective use of the limited experimental opportunities while maintaining sufficient evaluation of formulation stability.
- Accelerate Candidate Selection
By combining formulation development experience with an optimized screening workflow, the team was able to rapidly narrow the candidate formulations and identify a suitable formulation within approximately 11 weeks.
This accelerated approach helped reduce the development cycle while retaining a structured evaluation of formulation stability.
Results
Suitable Formulation Identified in Approximately 11 Weeks
The optimized formulation screening workflow enabled the team to identify a suitable formulation in approximately: 11 Weeks
For comparison, the supplier's case information indicates that formulation development in the industry typically takes approximately: 3–5 Months
This represents a substantially shorter development cycle than the stated typical industry timeframe.
Fig. 1. Stability evaluation of the selected formulation under different storage conditions over the study period.
Key Development Strategy
Experience-driven Screening
Formulation development experience was leveraged to identify appropriate screening priorities and maximize the value of limited experimental opportunities.
Optimized Screening Workflow
The screening workflow was rationally optimized to efficiently narrow formulation candidates within only two available screening rounds.
Accelerated Formulation Selection
A suitable formulation was identified in approximately 11 weeks, substantially shortening the stated typical 3–5 month industry development timeframe.
Key Outcomes
11-week Formulation Selection
A suitable formulation was identified in approximately 11 weeks through an optimized screening strategy.
Good Formulation Stability
Confirmation studies demonstrated favorable stability of the selected formulation under the evaluated conditions.
Successful IND Progression
The selected formulation successfully supported the program's progression to IND submission.
Project Outcome
The project demonstrated how an experience-driven and efficiently structured formulation screening strategy can help accelerate formulation development for a bispecific antibody under a highly constrained timeline.
With only two screening rounds available, the team optimized the formulation screening workflow based on its formulation development experience and successfully identified a suitable formulation in approximately 11 weeks, compared with a typical industry development timeframe of approximately 3–5 months.
Subsequent formulation confirmation demonstrated good stability of the selected formulation. The program successfully progressed to IND submission, demonstrating that the accelerated formulation development strategy effectively supported the broader clinical development timeline.
Related Services
